Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (5): 936-942. doi: 10.19723/j.issn.1671-167X.2022.05.021

Previous Articles     Next Articles

Clinical analysis of fertility-sparing therapy of patients with complex atypical hyperplasia and endometrial cancer

Chieko MORIMOTO,Yi-qin WANG,Rong ZHOU,Jian-liu WANG*()   

  1. Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China
  • Received:2022-06-15 Online:2022-10-18 Published:2022-10-14
  • Contact: Jian-liu WANG E-mail:wangjianliu@pkuph.edu.cn
  • Supported by:
    the National Key Technology Research and Development Program of China(2019YFC1005200);the National Key Technology Research and Development Program of China(2019YFC1005204)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To analyze the efficacy and prognosis of fertility-sparing therapy of the patient with complex atypical hyperplasia (CAH) and endometrial cancer (EC). Methods: Clinical data of 191 EC and CAH patients who received fertility-sparing therapy in Peking University People's Hospital between January 2009 and September 2021 were recruited retrospectively. Outcomes of remission, recurrence and pregnancy were analyzed. Results: (1) Efficacy and efficacy-related factors: The complete response (CR) rate was 86.1% (161/187) for all the patients, and the CR rate of the CAH patients were higher than that of the EC patients (92.7% vs. 79.1%, P=0.007), the CR rate was significant higher in the CAH patients (OR=2.786, P=0.035). (2) The recurrence rate was 19.3% (31/161), and the recurrence rate of the EC patients were much higher than that of the CAH patients (26.4% vs. 13.5%, P=0.039). The median recurrence time was 22.5 (9.0, 50.0) months. (3) The high risk factors of recurrence were pathological type of EC (χ2=4.880, P=0.027), without the use of metfor-min (χ2=7.075, P=0.008), longer time to complete remission (>7 months) (χ2=6.204, P=0.013), and no pregnancy (χ2=6.765, P=0.009). (4) Results of pregnancy and related factors: Among the patients who achieved CR, 108 patients had fertility willing with the pregnancy rate of 41.7% (45/108), and the live birth rate was 34.3% (37/108). The live birth rate was lower in EC than that in the CAH patients (28.6% vs. 42.4%, P=0.045). The median time to achieve pregnancy was 10.50 (5.75, 33.25) months. The pregnancy rate was significant higher in the patients with pregnancy history (OR=9.468, P < 0.001) and in those who received assisted reproductive therapy (OR=7.809, P < 0.001). Conclusion: Fertility-sparing therapy of CAH and EC patients is effective resulting in high disease remission and certain pregnancy. However, the high recurrence rate and low pregnancy rate are still key problems for EC and CAH patients, therefore close monitoring and follow-up are indicated.

Key words: Complex atypical hyperplasia, Endometrial carcinoma, Fertility preservation, Recurrence, Pregnancy

CLC Number: 

  • R737.33

Table 1

General condition of 191 EC and CAH patients"

Items Total (n=191) EC (n=92) CAH (n=99) P value
Age/years 33.0±5.7 32.5±5.4 33.4±5.9 0.244
Number of times of pregnancy
  0 121 (63.4) 59 (64.1) 62 (62.6) 0.829
  ≥1 70 (36.6) 33 (35.9) 37 (37.4)
Number of times of delivery
  0 157 (82.2) 78 (84.8) 79 (79.8) 0.368
  ≥1 34 (17.8) 14 (15.2) 20 (20.2)
BMI/(kg/m 2) 27.5±5.1 27.5±5.2 27.6±5.1 0.973
Complications
  Type Ⅱ diabetes 22 (11.5) 12 (13.0) 10 (10.1) 0.524
  PCOS 23 (12.0) 11 (12.0) 12 (12.1) 0.972
  Thyroid disease 11 (5.8) 6 (0.7) 5 (0.5) 0.663

Table 2

Logistic regression analysis of efficacy-related factors in 187 patients undergoing fertility-sparing therapy"

Items One factor analysis Multiple factors analysis
OR (95% CI) P value OR (95% CI) P value
Age/years ≥30 1.833 (0.653-5.147) 0.25 2.256 (0.717-7.100) 0.164
< 30 1 1
BMI/(kg/m2) ≥25 1.774 (0.664-4.738) 0.253 1.729 (0.631-4.733) 0.287
< 25 1 1
Pathology CAH 3.355 (1.336-8.424) 0.01 2.786 (1.073-7.235) 0.035
EC 1 1
Complication with PCOS Yes 0.588 (0.129-2.677) 0.492
No 1
Complication with diabetes Yes 1.036 (0.283-3.799) 0.957
No 1
Types of progesterone MPA 0.916 (0.194-4.330) 0.912
MA 1
Using metformin Yes 1.361 (0.582-3.180) 0.477
No 1

Figure 1

Kaplan-Meier cumulative complete response rate curve of fertility-sparing therapy for different pathological types EC, endometrial cancer; CAH, complex atypical hyperplasia."

Table 3

Logistic regression analysis of recurrence-related factors in patients with fertility-sparing therapy"

Items One factor analysis Multiple factors analysis
OR (95% CI) P value OR (95% CI) P value
Age/years ≥30 0.844 (0.361-1.973) 0.696
< 30 1
BMI/(kg/m2) ≥25 0.960 (0.416-2.218) 0.924
< 25 1
Pathology CAH 2.300 (1.031-5.134) 0.042 1.779 (0.729-4.343) 0.206
EC 1 1
Complication with PCOS Yes 0.712 (0.195-2.601) 0.608
No 1
Complication with diabetes Yes 0.821 (0.222-3.034) 0.768
No 1
Complication with thyroid disease Yes 0.689 (0.080-5.939) 0.735
No 1
Types of progesterone MPA 2.800 (0.845-9.283) 0.092 2.288 (0.653-8.014) 0.196
MA 1 1
Using metformin Yes 2.036 (0.890-4.660) 0.092 1.662 (0.691-3.994) 0.256
No 1 1
Using GnRHa Yes 1.960 (0.870-4.415) 0.104 1.667 (0.675-4.117) 0.268
No 1 1
Maintenance treatment Yes 0.734 (0.297-1.812) 0.502
No 1
Pregnancy Yes 1.024 (0.358-2.933) 0.964
No 1
Delivery Yes 2.13 (0.333-13.666) 0.424
No 1

Figure 2

Kaplan-Meier curve of cumulative recurrence rate for EC and CAH patients A, pathology; B, combination with metformin; C, with treatment time to complete response more than 7 months or not; D, with or without pregnancy. EC, endometrial cancer; CAH, complex atypical hyperplasia."

Table 4

Pregnancy status of 108 patients with fertility intention after achieving complete remission with the conservative treatment"

Items Total CAH (n=89) EC (n=72) P value
Patients with fertility intention 108 59 49
Patients with assisted human reproduction 34 19 15
Patients with pregnancy (pregnancy times) 45 (50) 26 (29) 19 (21)
Patients with delivery (delivery times) 39 (37) 27 (25) 12 (12)
Pregnancy rate/% 41.7 44.1 38.8 0.579
Fertility rate/% 34.3 42.4 28.6 0.045
Pregnancy duration/months, M (P25, P75) 10.50 (5.75, 33.25) 9.00 (2.50, 29.50) 13.00 (7.00, 46.50) 0.196

Table 5

Logistic regression analysis of pregnancy-related factors of the 108 patients with fertility intention"

Items One factor analysis Multiple factors analysis
OR (95% CI) P value OR (95% CI) P value
Age/years ≥30 0.773 (0.338-1.772) 0.543
< 30 1
Pregnancy history Yes 10.711 (4.206-27.271) < 0.001 9.468 (2.928-30.618) < 0.001
No 1 1
BMI/(kg/m2) ≥25 0.731 (0.324-1.647) 0.45
< 25 1
Complication with PCOS Yes 2.508 (0.762-8.253) 0.13 2.209 (0.374-13.046) 0.382
No 1 1
Complication with diabetes Yes 0.247 (0.051-1.186) 0.081 0.627 (0.061-6.432) 0.695
No 1 1
Complication with thyroid disease Yes 0.999
No
Pathology CAH 0.804 (0.372-1.738) 0.579
EC 1
Using metformin Yes 0.822 (0.379-1.785) 0.621
No 1
Using GnRHa Yes 1.099 (0.469-2.576) 0.828
No 1
Assisted human reproduction Yes 12.768 (4.763-34.244) < 0.001 7.809 (2.600-23.457) < 0.001
No 1
Recurrence Yes 1.024 (0.358-2.933) 0.964
No 1
1 Corzo C , Barrientos SN , Westin SN , et al. updates on conservative management of endometrial cancer[J]. J Minim Invasive Gynecol, 2018, 25 (2): 308- 313.
doi: 10.1016/j.jmig.2017.07.022
2 中国研究型医院学会妇产科专业委员会. 早期子宫内膜癌保留生育功能治疗专家共识[J]. 中国妇产科临床杂志, 2019, 20 (4): 369- 373.
doi: 10.13390/j.issn.1672-1861.2019.04.025
3 Silverberg SG , Makowski EL , Roche WD . Endometrial carcinoma in women under 40 years of age: Comparison of cases in oral contraceptive users and non-users[J]. Cancer, 1977, 39 (2): 592- 598.
doi: 10.1002/1097-0142(197702)39:2<592::AID-CNCR2820390233>3.0.CO;2-O
4 Gynecologic Oncology Branch of the Chinese Medical Association . Guidelines for fertility-preserving treatment of gynecological malignant tumors (Chinese)[J]. Chin J Obstet Gynecol, 2014, 4, 243- 248.
5 Park JY , Kim DY , Kim JH , et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002)[J]. Eur J Cancer, 2013, 49 (4): 868- 874.
doi: 10.1016/j.ejca.2012.09.017
6 Chen M , Jin Y , Li Y , et al. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer[J]. Int J Gynaecol Obstet, 2016, 132 (1): 34- 38.
doi: 10.1016/j.ijgo.2015.06.046
7 Hahn HS , Yoon SG , Hong JS , et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer[J]. Int J Gynecol Cancer, 2009, 19 (6): 1068- 1073.
doi: 10.1111/IGC.0b013e3181aae1fb
8 Wang CJ , Chao A , Yang LY , et al. Fertility-preserving treatment in young women with endometrial adenocarcinoma: A long-term cohort study[J]. Int J Gynecol Cancer, 2014, 24 (4): 718- 728.
doi: 10.1097/IGC.0000000000000098
9 Ohyagi-Hara C , Sawada K , Aki I , et al. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: Our experience and a review of the literature[J]. Arch Gynecol Obstet, 2015, 291 (1): 151- 157.
doi: 10.1007/s00404-014-3417-z
10 Gunderson CC , Fader AN , Carson KA , et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review[J]. Gynecologic Oncology, 2012, 125 (2): 477- 482.
doi: 10.1016/j.ygyno.2012.01.003
11 Yang YF , Liao YY , Liu XL , et al. Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment[J]. J Gynecol Oncol, 2015, 139 (3): 419- 423.
doi: 10.1016/j.ygyno.2015.10.015
12 Zhou H , Cao D , Yang J , et al. Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women[J]. Int J Gynecol Cancer, 2017, 27 (6): 1178- 1182.
doi: 10.1097/IGC.0000000000001008
13 Pronin SM , Novikova OV , Andreeva JY , et al. Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential[J]. Int J Gynecol Cancer, 2015, 25 (6): 1010- 1014.
doi: 10.1097/IGC.0000000000000467
14 Dursun P , Erkanli S , Güzel AB , et al. A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer[J]. Int J Gynaecol Obstet, 2012, 119 (3): 270- 273.
doi: 10.1016/j.ijgo.2012.06.010
15 Mitsuhashi A , Habu Y , Kobayashi T , et al. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients[J]. J Gynecol Oncol, 2019, 30 (6): e90.
doi: 10.3802/jgo.2019.30.e90
16 柳晓肃, 郭红燕, 宋雪凌, 等. 早期高分化子宫内膜癌及子宫内膜不典型增生患者保留生育功能治疗的结局分析[J]. 实用妇产科杂志, 2020, 36 (9): 685- 689.
17 Pashov AI , Tskhay VB , Ionouchene SV , et al. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: A pilot study[J]. Gynecol Endocrinol, 2012, 28 (7): 559- 561.
doi: 10.3109/09513590.2011.649813
18 Kim MK , Seong SJ , Kim YS , et al. Combined medroxyproges-terone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer[J]. Am J Obstet Gynecol, 2013, 209 (4): 358.e1- e4.
doi: 10.1016/j.ajog.2013.06.031
19 Cade TJ , Quinn MA , Rome RM , et al. Progestogen treatment options for early endometrial cancer[J]. BJOG, 2010, 117 (7): 879- 884.
doi: 10.1111/j.1471-0528.2010.02552.x
20 Zhang Z , Huang H , Feng F , et al. A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer[J]. J Gynecol Oncol, 2019, 30 (4): e61.
doi: 10.3802/jgo.2019.30.e61
21 Gallos ID , Yap J , Rajkhowa M , et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis[J]. Am J Obstet Gynecol, 2012, 207 (4): 261- 266.
[1] Xinyi LI, Jinxia ZHAO, Rong MU. Impact of aspirin use on pregnancy outcomes in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1074-1080.
[2] Fengyi HU, Qingyang MENG, Nayun CHEN, Jianing WANG, Zhenlong LIU, Yong MA, Yuping YANG, Xi GONG, Cheng WANG, Ping LIU, Weili SHI. Clinical efficacy of arthroscopic medial patellofemoral complex reconstruction for recurrent patellar dislocation with high-grade trochlear dysplasia [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 947-955.
[3] Shuhan YANG, Yixin LI, Haoliang CUI, Youxin WANG, Yuying WU, Mingyue WANG, Yifan YANG, Nur Enkar, Lei YANG, Hui WANG. Associations of metabolic dysfunction-associated steatotic liver disease and cardiometabolic risk factor abnormalities with adverse pregnancy outcomes [J]. Journal of Peking University (Health Sciences), 2025, 57(3): 487-495.
[4] Wen BIAN, Wenjun ZHOU, Tianchen WU, Peijing ZHU, Yinuo CHEN, Pengbo YUAN, Xueju WANG, Ying WANG, Yuan WEI, Yangyu ZHAO. Perinatal outcomes of single intrauterine fetal demise in monochorionic diamniotic twins [J]. Journal of Peking University (Health Sciences), 2025, 57(3): 592-598.
[5] Wenqiong WANG, Yuke HOU, Chun LI, Xuewu ZHANG. Predictors of adverse pregnancy outcomes in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2025, 57(3): 599-603.
[6] Junjuan YANG, Lei ZHANG, Yan ZHANG. Pregnancy complicated by patent urachus: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 393-395.
[7] Fangfei XIE, Hong QIAO, Boya LI, Cui YUAN, Fang WANG, Yu SUN, Shuangling LI. Severe malnutrition during pregnancy complicated with acute pyelonephritis causing sepsis, refractory septic shock and multiple organ failure: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(1): 202-207.
[8] Yukai LI, Hongyan WANG, Liang LUO, Yun LI, Chun LI. Clinical significance of antiphospholipid antibodies in Behcet disease with thrombosis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1036-1040.
[9] Mingxia WANG, Ling DING, Min WANG, Chanjuan ZOU, Siyu YAN, Yingwen LIANG, Weijia WANG, Shanzhi HE. Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1119-1125.
[10] Yujing ZHU, Lei WANG, Chengyin LYU, Wenfeng TAN, Miaojia ZHANG. Analysis of clinical features of ruccrent interstitial lung disease in patients with anti-EJ positive antisynthetase syndrome [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 980-986.
[11] Yuqing LI,Biao WANG,Peng QIAO,Wei WANG,Xing GUAN. Medium to long-term efficacy of tension-free vaginal tape procedure in the treatment of female recurrent stress urinary incontinence [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 600-604.
[12] Huichao MA,Jun LI,Yongqing WANG. Clinical characteristics of pregnancy complicated with inflammatory bowel disease [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 260-266.
[13] Yangyang LI,Lin HOU,Zijun MA,Shanyamei HUANG,Jie LIU,Chaomei ZENG,Jiong QIN. Association of pregnancy factors with cow's milk protein allergy in infants [J]. Journal of Peking University (Health Sciences), 2024, 56(1): 144-149.
[14] Fang-ning YOU,Liang LUO,Xiang-jun LIU,Xue-wu ZHANG,Chun LI. Analysis of pregnancy outcomes, disease progression, and risk factors in patients with undifferentiated connective tissue disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1045-1052.
[15] Yu-fei LI,Ya-ni YAN,Jia-yang JIN,Chun LI,Qiu-yan PEI. Clinical characteristics of fetal cardiac disease in patients with anti-SSA antibody positive [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1053-1057.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd